Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2009

Diabetes Foundation Allies with Genomics Institute of the Novartis Research Foundation to Accelerate R&D

  • The Juvenile Diabetes Research Foundation (JDRF) and the Genomics Institute of the Novartis Research Foundation (GNF) agreed to work together to advance diabetes drug R&D. The initial focus will be on pancreatic beta-cell regeneration and survival to restore beta-cell function in diabetes.

    The program builds on current JDRF funding at GNF that has resulted in the discovery of beta-cell regeneration drug targets and candidates. It also allows for the inclusion of JDRF-funded projects and other discoveries. The aim is to take a number of drug candidates into the clinic over the four-year term of the initiative.

    “Through this collaboration with JDRF, we are looking to create a unique program of translational research that fully exploits the strengths of each partner to produce a continuous source of novel insights, drug targets, and drug candidates,” says Peter Schultz, Ph.D., lead GNF investigator and institute director.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »